Bekescsaba

• A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease Ended recruitment
  2023-504736-18-00 10 2018-07-26 Moderately to Severely Active Crohn's Disease
• Long Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis. Ended recruitment
  2023-505699-31-00 5 2017-01-02 Ulcerative Colitis
• A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended
  2023-507705-34-00 5 2025-08-29 Moderate to Severe Active Ulcerative Colitis
• A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia Ended
  2024-511331-96-00 4 2024-07-04 Mixed Dyslipidemia
• A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis Ended
  2023-503315-15-00 4 2023-12-20 Thrombolysis of symptomatic proximal vein thrombosis
• A Study to Investigate Bowel Urgency in Adults with Moderately to Severely Active Ulcerative Colitis Treated with Mirikizumab Ended
  2022-502393-16-00 5 2023-09-06 Moderately to Severely Active Ulcerative Colitis
• Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended
  2023-506046-24-00 4 2023-07-03 Ulcerative Colitis (UC)
• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended
  2022-500535-36-01 5 2023-06-12 Moderately to severely active ulcerative colitis
• A Phase 2 Study of the Effects of Ponsegromab on Health-Related Quality of Life and Safety in Patients With Heart Failure (GARDEN-TIMI 74) Ended
  2023-509747-27-00 4 2023-05-18 Heart failure
• Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended
  2022-501585-22-00 5 2023-05-11 Atopic Dermatitis
• Phase 2 Study to Assess Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction (≤45%) After Myocardial I … Ended
  2023-507569-24-00 4 2022-06-20 Myocardial Infarction, Acute Heart Failure, Left Sided
• Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis Ended
  2023-506004-93-00 4 2022-03-01 Ulcerative Colitis (UC)
• VTX002 versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis Ended
  2023-509233-39-00 4 2022-01-20 Moderately to Severely Active Ulcerative Colitis
• A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended
  2022-500881-80-00 5 2021-10-29 Chronic Heart Failure With Reduced Ejection Fraction
• A clinical study of tulisokibart for the treatment of ulcerative colitis (MK-7240-005) Ended
  2023-509741-12-00 4 2021-09-23 Ulcerative Colitis
• A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenan … Ended
  2024-513569-38-00 10 2021-07-09 Crohn's Disease
• Ertugliflozin Pediatric Study Ended
  2022-501085-21-00 5 2019-11-29 Type 2 Diabetes Mellitus
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease Ended
  2024-511553-22-00 5 2018-10-05 Moderately to Severely Active Crohn's Disease
• A randomized, phase 3 multicenter clinical trial to confirm the clinical efficacy and evaluate the safety of linaprazan glurate compared to … Ended
  2025-522750-39-00 5 Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)

Showing 49–68 of 68 trials